Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Institution
- Publication
- Publication Type
Articles 1 - 4 of 4
Full-Text Articles in Entire DC Network
What Is The Best First Agent To Give To A Patient With Acute Ischaemic Stroke? Aspirin, Heparin, Clopidogrel, Cilostazol Or Dipyridamole, Maria Khan, Ayeesha Kamran Kamal
What Is The Best First Agent To Give To A Patient With Acute Ischaemic Stroke? Aspirin, Heparin, Clopidogrel, Cilostazol Or Dipyridamole, Maria Khan, Ayeesha Kamran Kamal
Section of Neurology
No abstract provided.
Pregnancy Outcome In Women With Antiphospholipid Syndrome On Low-Dose Aspirin And Heparin: A Retrospective Study., T. Naru, Rozilla Sadia Khan, R. Ali
Pregnancy Outcome In Women With Antiphospholipid Syndrome On Low-Dose Aspirin And Heparin: A Retrospective Study., T. Naru, Rozilla Sadia Khan, R. Ali
Department of Obstetrics & Gynaecology
This retrospective review of hospital records analysed pregnancy outcome with 2 different treatments for women with recurrent miscarriage diagnosed with antiphospholipid syndrome in the index pregnancy. Of 64 women, 29 had received aspirin and 35 aspirin plus heparin. Pregnancy-induced hypertension, prematurity, intrauterine growth restriction and neonatal death were considered as maternal and fetal complications. There were no significant differences in antenatal and maternal complications between the groups. However, there were significant differences in mean anticardiolipin IgG antibody levels. Aspirin alone or in combination with parin was equally efficacious in women with antiphospholipid syndrome and recurrent miscarriage.
The Effects Of Anticoagulant Choice And Sample Processing Time On Hematologic Values Of Juvenile Whooping Cranes, Joan Maurer, Betsy Reichenberg, Cristin Kelley, Barry K. Hartup
The Effects Of Anticoagulant Choice And Sample Processing Time On Hematologic Values Of Juvenile Whooping Cranes, Joan Maurer, Betsy Reichenberg, Cristin Kelley, Barry K. Hartup
Proceedings of the North American Crane Workshop
Blood collected from juvenile whooping cranes (Grus americana) in 2007 and 2008 was divided and placed in either the anticoagulant lithium heparin (LiHep) or tri-potassium ethylenediaminetetraacetic acid (K3EDTA) for diagnostic hematology. Thin smears were prepared from the anticoagulated blood in the field with no delay and in the laboratory after a 4-6-hour delay, and then used to determine differential and total leukocyte counts. Manual heterophil and eosinophil counts were greater in LiHep-treated samples compared to K3EDTA samples (P < 0.05), but there was no difference in the total leukocyte concentration or differential leukocyte counts between anticoagulants based on blood smears prepared with no delay (n = 15). Marked differences were noted in relative heterophil (P < 0.05) and lymphocyte (P < 0.05) counts and total leukocyte (P < 0.05) concentrations of K3EDTA-treated samples processed after the delay (n = 7), suggesting a negative effect on lymphocyte integrity from the anticoagulant. Microscopically, lymphocytes were more intact and easily differentiated from thrombocytes in LiHep-treated samples than K3EDTA, but modest thrombocyte clumping in the LiHep samples was a concern. Either anticoagulant appears adequate for diagnostic hematology in juvenile whooping cranes based on this limited analysis, but blood smears should be prepared immediately under controlled conditions for best results.
Heparanase Drives The Aggressive Myeloma Phenotype: Preclinical Development Of A Heparanase Inhibitor For The Treatment Of Multiple Myeloma, Joe Ritchie
All ETDs from UAB
Heparanase, an endoglycosidase which cleaves heparan sulfate chains at specific sites, is rarely expressed in normal tissues but becomes evident in many human cancers. We have previously shown that heparanase promotes myeloma growth and angiogenesis through modulation of the tumor microenvironment. Recognition that heparanase drives the aggressive myeloma phenotype has led to new strategies designed to therapeutically target this enzyme. SST0001, a non-anticoagulant heparin that is 100% N-acetylated and 25% glycol split, was previously described as a potent inhibitor of heparanase activity in vitro, and, in limited in vivo experiments, SST0001 was identified to have efficacy as an anti-tumor agent …